A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...

We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...

University of Washington-led research, published in 2023, discovered microglia in the brains of people with Alzheimer's ...

Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...

A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence the progression of neurodegeneration remains something of a black box ...

Diagnosing Alzheimer's years before you have symptoms. That's where research takes us. New, effective treatments are making a ...

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...

Ann Lange was diagnosed with Alzheimer's in 2015, but with the help of clinical trials her disease has not progressed past ...

The global neuromodulation device market will be worth $11.4bn by 2033, as per a market model from GlobalData.

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...